Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Boston Scientific Corp (NYSE: BSX) closed at $93.74 down -0.42% from its previous closing price of $94.14. In other words, the price has decreased by -$0.42 from its previous closing price. On the day, 7.27 million shares were traded. BSX stock price reached its highest trading level at $93.99 during the session, while it also had its lowest trading level at $92.815.
Ratios:
For a deeper understanding of Boston Scientific Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 101.21 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 36.34. For the most recent quarter (mrq), Quick Ratio is recorded 0.96 and its Current Ratio is at 1.51. In the meantime, Its Debt-to-Equity ratio is 0.51 whereas as Long-Term Debt/Eq ratio is at 0.49.
On September 08, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $125.
On June 16, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $118.Leerink Partners initiated its Outperform rating on June 16, 2025, with a $118 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 01 ’25 when Butcher Arthur C sold 17,313 shares for $101.55 per share. The transaction valued at 1,758,189 led to the insider holds 23,600 shares of the business.
ARTHUR C BUTCHER bought 17,313 shares of BSX for $1,758,188 on Dec 01 ’25. On Nov 06 ’25, another insider, Zane Ellen M, who serves as the Director of the company, sold 12,891 shares for $98.28 each. As a result, the insider received 1,266,978 and left with 24,134 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BSX now has a Market Capitalization of 138964107264 and an Enterprise Value of 149970124800. As of this moment, Boston’s Price-to-Earnings (P/E) ratio for their current fiscal year is 50.14, and their Forward P/E ratio for the next fiscal year is 26.98. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.66. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.18 while its Price-to-Book (P/B) ratio in mrq is 5.94. Its current Enterprise Value per Revenue stands at 7.751 whereas that against EBITDA is 29.574.
Stock Price History:
The Beta on a monthly basis for BSX is 0.67, which has changed by -0.04105121 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, BSX has reached a high of $109.50, while it has fallen to a 52-week low of $85.98. The 50-Day Moving Average of the stock is -3.77%, while the 200-Day Moving Average is calculated to be -6.92%.
Shares Statistics:
For the past three months, BSX has traded an average of 8.82M shares per day and 7597710 over the past ten days. A total of 1.48B shares are outstanding, with a floating share count of 1.48B. Insiders hold about 0.39% of the company’s shares, while institutions hold 93.36% stake in the company. Shares short for BSX as of 1767139200 were 20010940 with a Short Ratio of 2.27, compared to 1764288000 on 18734072. Therefore, it implies a Short% of Shares Outstanding of 20010940 and a Short% of Float of 1.35.
Earnings Estimates
The stock of Boston Scientific Corp (BSX) is currently drawing attention from 27.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0.8, with high estimates of $0.85 and low estimates of $0.75.
Analysts are recommending an EPS of between $3.06 and $2.98 for the fiscal current year, implying an average EPS of $3.04. EPS for the following year is $3.47, with 32.0 analysts recommending between $3.62 and $3.35.
Revenue Estimates
A total of 27 analysts believe the company’s revenue will be $5.28B this quarter.It ranges from a high estimate of $5.33B to a low estimate of $5.25B. As of. The current estimate, Boston Scientific Corp’s year-ago sales were $4.56BFor the next quarter, 27 analysts are estimating revenue of $5.2B. There is a high estimate of $5.3B for the next quarter, whereas the lowest estimate is $5.12B.
A total of 31 analysts have provided revenue estimates for BSX’s current fiscal year. The highest revenue estimate was $20.16B, while the lowest revenue estimate was $20.03B, resulting in an average revenue estimate of $20.07B. In the same quarter a year ago, actual revenue was $16.75BBased on 31 analysts’ estimates, the company’s revenue will be $22.39B in the next fiscal year. The high estimate is $23.86B and the low estimate is $22.08B.
